A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Inclusion Criteria (For renal impaired subjects): * Classification by renal function based on eGFR * Clinical, ECG, and laboratory findings consistent with renal dysfunction * BMI of 18.0 to 38.0 kg/m2 inclusive * Women of child bearing potential (WOCBP) and sexually active fertile men with partners who are WOCBP must use non-hormonal highly effective birth control * Slightly different inclusion criteria are defined in the protocol for healthy subjects Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening * Evidence of rapidly deteriorating renal function, defined as a screening eGFR that has decreased from a previous eGFR by ≥ 50% within the last 3 months * Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease or gastrointestinal surgery (including cholecystectomy) that could impact the absorption of study drug * Any major surgery within 4 weeks of study drug administration. * Other protocol defined exclusion criteria could apply